Click Fraud Protection PharMerica Long-Term Pharmacy to Pay U.S. Government $31.5 Million for Allegedly Violating Controlled Substance Act and False Claims Act - TZ Legal - Fraud Fighters
TZ Legal – Fraud Fighters Logo
HomeNewsPharMerica Long-Term Pharmacy to Pay U.S. Government $31.5 Million for Allegedly Violating Controlled Substance Act and False Claims Act

PharMerica Long-Term Pharmacy to Pay U.S. Government $31.5 Million for Allegedly Violating Controlled Substance Act and False Claims Act

Date Published
May 21, 2015

On May 15, 2015, the Department of Justice (DOJ) announced that PharMercia Corporation, a comprehensive long-term provider of pharmacy services, operating across the country, agreed to pay the U.S. Government $31.5 million for allegedly violating the Controlled Substance Act (CSA) by knowingly dispensing Schedule II controlled drugs to residences of long-term care facilities without a valid prescription from a physician.  In addition, PharMercia also allegedly violated the False Claims Act (FCA) when it submitted claims to Medicare for these improperly dispensed drugs.

The Controlled Substance Act (CSA) is a federal law that regulates the prescribing and dispensing of psychoactive drugs, including narcotics, hallucinogens, depressants, and stimulants.  Schedule II controlled drugs are drugs or other substances that have a high potential for abuse.  According to the lawsuit filed on behalf of the government by Jennifer Denk, a pharmacist formerly employed by PharMerica and the whistleblower in this qui tam case, PharMercia allowed nursing home staff to administer Schedule II controlled substances, such as oxycodone and fentanyl, to its long-term residences — mostly elderly patients living in nursing homes — without obtaining a valid written prescription from their doctors.  In addition, the government alleged that PharMerica also allowed pharmacists to dispense the drugs without confirming that the prescriptions were legitimately approved by the patient’s doctor or medically necessary.  This type of practice is a violation of the CSA.

In the lawsuit, the government also accused PharMercia of billing Medicare for Schedule II medication administered during the long-term care of patients in nursing homes — medication that did not get the proper approval from the patient’s doctor.  Billing for improperly dispense drugs is a violation of the FCA and is considered Medicare fraud and $23.5 million of the settlement was allocated to settling the FCA claims.

If you have information about a person or company dispensing CSA prescription drugs that have not been approved by a health care provider, or billing Medicaid or Medicare for unapproved drugs, do not hesitate to take action. It is possible that you might be able to bring your own qui tam lawsuit under the False Claims Act, acting as a whistleblower on behalf of the U.S. government. A whistleblower who files a case against a company that has committed fraud against the government, may receive compensation of up to 30 percent of the amount ultimately recovered by the government.

Before filing your lawsuit, be sure to consult with an attorney familiar with the intricacies of the False Claims Act and qui tam lawsuits, as these attorneys are best equipped to help protect your rights and help you gain your share of any monetary reward from a potential settlement.

If you would like to consult with one of our False Claims Act attorneys concerning Medicare fraud or other forms of healthcare fraud, please fill out our Confidential Case Evaluation form, or call (202) 973-0900 to speak with a lawyer at the law office of Tycko & Zavareei LLP.

How can we help you?

Confidential Case Evaluation

Our experienced qui tam attorneys are available for a confidential, no-cost, no-commitment, initial evaluation of your case. Call us now at (202) 973-0900, or begin the process by completing our Confidential Case Evaluation Form.
Start The Process

Get in Touch

We Are Just A Click Away